Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alexion Pharmaceuticals, Inc.
This study is an open label extension study to confirm the long term safety and efficacy of eculizumab in subjects with relapsing NMO who have completed the initial double-blind, randomized, placebo-controlled trial ECU-NMO-301.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Patient completed the ECU-NMO-301 trial
2. Patient has given written informed consent
You may not be if
1. Patients who have withdrawn from the ECU-NMO-301 trial as a result of an AE related to trial drug
2. Female patients who are pregnant, breastfeeding, or intend to conceive during the course of the trial
Clareo Health | An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
